SYRE Stock Forecast & Price Target

Spyre Therapeutics is attractive fundamentally because its diversified, internally owned pipeline spans three distinct mechanisms—α4β7, TL1A, and IL-23—that have already shown proof-of-concept and create multiple shots on goal through both monotherapy and combination regimens. The core IBD thesis remains intact despite the rheumatology setback for SPY072, since the company is refocusing on areas with stronger clinical validation, while SKYLINE Part B is progressing ahead of expectations, enrollment has been expanded by ~15%, and topline data for all three combinations are now guided to 3Q27. Financially, Spyre ended 3Q26 with about $1.07B in cash and investments, raised roughly $396MM net thereafter for pro forma cash of about $1.47B, and expects runway into 2H29, giving it time to execute without near-term financing pressure.

Spyre Therapeutics is viewed negatively because its SPY072 program has already failed to clear the company’s own advancement threshold in rheumatoid arthritis, even though August 2026 data showed proof-of-mechanism for TL1A. The remaining SKYWAY readouts in psoriatic arthritis and active axial spondyloarthritis are not expected until 4Q26, leaving the investment case dependent on future clinical success across two more indications with separate endpoints and modestly sized cohorts. With no disclosed commercial revenue and a single focus on developing biopharmaceutical products for IBD and immune-mediated disease, the company remains highly exposed to binary trial risk, delayed value realization, and potential dilution from ongoing development costs.